Document Detail


Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo.
MedLine Citation:
PMID:  17245119     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Chk1 and Chk2 kinases are critically involved in modulating DNA damage checkpoints. In particular, Chk1, a key activator of the S-phase DNA damage response, may be involved in resistance to genotoxic therapies that target DNA synthesis. We studied the in vitro and in vivo effects of EXEL-9844 (XL844), a potent, orally available, and specific inhibitor of Chk1 and Chk2, in combination with gemcitabine. In clonogenic assays using multiple cell lines in vitro, EXEL-9844 had only minor effects as a single agent but substantially enhanced gemcitabine-induced cell killing. Correspondingly, in PANC-1 cells, EXEL-9844 increased gemcitabine-induced H2AX phosphorylation, blocked Cdc25A phosphorylation, and induced premature mitotic entry. In a PANC-1 xenograft model, EXEL-9844 significantly enhanced gemcitabine antitumor activity but had limited effect as a single agent. Together, these data show that cell cycle checkpoint inhibitors may have significant clinical utility in potentiating the activity of gemcitabine.
Authors:
David J Matthews; F Michael Yakes; Jason Chen; Michele Tadano; Lester Bornheim; Douglas O Clary; Albert Tai; Jill M Wagner; Nicole Miller; Yong D Kim; Scott Robertson; Louis Murray; Larry M Karnitz
Related Documents :
8552379 - Adenovirus-mediated p16/cdkn2 gene transfer induces growth arrest and modifies the tran...
16507989 - Normal cells, but not cancer cells, survive severe plk1 depletion.
11306489 - The proteasome inhibitor ps-341 inhibits growth, induces apoptosis, and overcomes drug ...
20371709 - Sirt inhibitors induce cell death and p53 acetylation through targeting both sirt1 and ...
11095619 - Induction of cell cycle entry and cell death in postmitotic lens fiber cells by overexp...
10825139 - Efficient induction of cell death by adenoviruses requires binding of e1b55k and p53.
1455519 - How to make a glycoinositol phospholipid anchor.
7852279 - Coordinate modulation of melanogenesis and type i trimer collagen secretion by type i c...
23405949 - Absolute quantification of cell-bound dna aptamers during selex.
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2007-01-07
Journal Detail:
Title:  Cell cycle (Georgetown, Tex.)     Volume:  6     ISSN:  1551-4005     ISO Abbreviation:  Cell Cycle     Publication Date:  2007 Jan 
Date Detail:
Created Date:  2007-02-01     Completed Date:  2007-04-09     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  101137841     Medline TA:  Cell Cycle     Country:  United States    
Other Details:
Languages:  eng     Pagination:  104-10     Citation Subset:  IM    
Affiliation:
Exelixis Inc., South San Francisco, California 94083, USA. matthews@exelixis.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antimetabolites, Antineoplastic / pharmacology*
Cells, Cultured
Deoxycytidine / analogs & derivatives*,  pharmacology
Dose-Response Relationship, Drug
Female
Genes, cdc / drug effects*,  physiology
Mice
Mice, Nude
Protein Kinases / metabolism
Protein-Serine-Threonine Kinases / metabolism
S Phase / drug effects*,  physiology
Xenograft Model Antitumor Assays / methods
Chemical
Reg. No./Substance:
0/Antimetabolites, Antineoplastic; 951-77-9/Deoxycytidine; B76N6SBZ8R/gemcitabine; EC 2.7.-/Protein Kinases; EC 2.7.1.11/checkpoint kinase 2; EC 2.7.11.1/Checkpoint kinase 1; EC 2.7.11.1/Protein-Serine-Threonine Kinases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  CYFIP2, a direct p53 target, is leptomycin-B sensitive.
Next Document:  Bilirubin and biliverdin treatment of atherosclerotic diseases.